Chen Y, Ke L, Meng L, Yang Q, Tong Z, Pan Y, Li W, Li J
Products in this category Semaglutide: GLP-1 analog research material with multiple vial-size options
It will be interesting to see how these agents reshape obesity and metabolic disease treatment in the coming years
Expected timeline: Week 1-4: Inflammation reduction, potential nerve symptom improvement Week 4-8: Progressive healing, reduced radicular symptoms Week 8-12: Structural improvements developing, continued symptom reduction Week 12-16: Consolidation of gains, assessment for continued protocol Important notes: Disc herniations vary enormously in severity
Diabetic nephropathy
It is the more serious statement that nobody has looked, and the biology that drives the healing signal is the same biology that warrants the question